Navigation Links
First Potential Lupus-Specific Treatment in Sight
Date:7/19/2009

BENLYSTA(TM) SUCCESSFUL IN FIRST OF TWO PIVOTAL CLINICAL TRIALS

WASHINGTON, July 20 /PRNewswire-USNewswire/ -- Today, Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) announced positive results from a year-long clinical trial of BENLYSTA for treating lupus. When the 52-week study concluded, the lupus patients who were treated with BENLYSTA had improvement in overall disease activity without clinically significant flare-ups in one or more isolated organs when compared to patients who received the placebo (inactive agent). The patients receiving BENLYSTA also were able to reduce their intake of steroid medications. The study is the largest ever to be completed for lupus and the first Phase III (late stage) trial of a new biologic immune therapy for lupus to succeed in meeting its primary endpoint and most of its secondary endpoints.

Sandra C. Raymond, President and Chief Executive Officer of the Lupus Foundation of America (LFA) issued the following statement.

"For people with lupus and their loved ones, this is an historic day! With no new drugs for more than 50 years, since the Eisenhower Administration, the news today indicates that it is possible to develop new, safe, and effective therapies for lupus. We are greatly encouraged by the positive top-line data which shows that HGS' 52-week BENLYSTA study met its primary endpoint. These results provide hope that this complex chronic autoimmune disease can be brought under control and that, eventually, a cure can be found for the estimated 1.5 million Americans and more than 5 million people worldwide living with lupus.

"We look forward to hearing the results, this fall, of a longer-term Phase III clinical study of BENLYSTA. The data from both studies will be evaluated by the U.S. Food and Drug Administration (FDA). Should the FDA ultimatel
'/>"/>

SOURCE Lupus Foundation of America
Copyright©2009 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013   Polymer Technology Systems, ... Aegis Health Group to integrate the CardioChek ... programs administered by health systems across the country. ... PTS and distributed through Hanson Medical Systems ... HDL cholesterol, LDL cholesterol, triglycerides, and glucose. ...
(Date:6/17/2013)... 2013  Hanger, Inc. (NYSE:  HGR) today announced the ... its senior secured facilities to an aggregate of up ... credit agreement includes a $200 million revolving credit facility ... credit agreement was comprised of a $100 million revolving ... new facility matures on June 17, 2018, and is ...
(Date:6/17/2013)... , June 17, 2013 BioMed Realty Trust, Inc. ... of directors has declared a second quarter 2013 dividend of ... to an annualized dividend of $0.94 per common share. ... 15, 2013 to stockholders of record at the close of ... Realty Trust BioMed Realty delivers optimal real estate ...
Breaking Medicine Technology:Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 2Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 3BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 3
(Date:6/18/2013)... (PRWEB) June 18, 2013 Exposed Skin Care ... thousands of acne suffers of all ages finally achieve the ... acne treatment products, this new acne clearing system combines the ... and prevent new acne from forming. , After ... believes these products are some of the most effective available ...
(Date:6/18/2013)... 19, 2013 "What if adding one ... could boost your health and well-being? Well, there is ... Sublime Beauty®. "It is called Skin Brushing ." ... became a lost art. Now, people are rediscovering this ... Brushing, and so do certain health conscious people. Sublime ...
(Date:6/18/2013)... PA, June 19, 2013 Recent studies linking ... of bullying-related suicide among young people, led the ... assemble an expert panel to focus on these ... the complex relationship between youth involvement in bullying ... among youth is a significant public health problem, ...
(Date:6/18/2013)... Parker Waichman LLP, a national law ... by dangerous drugs and medical devices, has filed a ... that she was injured by transvaginal mesh ... the U.S. District Court for the Southern District of ... litigation entitled In Re: American Medical Systems, Inc., Pelvic ...
(Date:6/18/2013)... Fla. (PRWEB) June 19, 2013 An ... When Linda Christina Beauregard was diagnosed with breast cancer, ... In her new book, “I Gave Myself Cancer, I ... Life” (published by Balboa Press), Beauregard explains how changing ... cancer. , "Sick people have been made to feel ...
Breaking Medicine News(10 mins):Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3Health News:The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty® 2Health News:Bullying and suicide among youth is a public health problem 2Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 2Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 3Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 4Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2
... Department of Orthopaedic Surgery at the University of Pittsburgh School of ... Center (UPMC) for Sports Medicine will be installed as the 37th ... Saturday, July 12, 2008, during the Society,s Annual Meeting in Orlando, ... ...
... NASHVILLE, Tenn., July 2 Ambulatory Services of,America, ... Dallas, LLP, its,sixth joint venture to provide outpatient ... joint venture between ASA,s subsidiary, Radiation,Oncology Services of ... Landmark,Radiation Dallas LP. ROSA of North Dallas will ...
... Senate, derailing a critical bipartisan bill that would have ... to physicians who,treat Medicare patients, and made significant improvements ... Last week, Sen. Richard Lugar joined a minority of ... people on Medicare continued,access to their doctors and improved ...
... childbirth as most common reason for hospitalizations, analysis finds ... more than 1.2 million Americans -- roughly equivalent to ... a federal government analysis of hospital admissions and costs ... the most common reason for admission to hospital, and ...
... company with an outstanding track record in the ... technologies, announced availability of the Genomatix Genome Analyzer ... first integrated hardware / software solution for in-depth ... (NGS) devices as provided by Illumina, Roche (454), ...
... simplex out of hiding could bring about a cure, scientists ... Americans are afflicted by breakouts of unsightly cold sores, caused ... finally offering them the possibility of a cure. , Scientists ... herpes simplex 1 slips into dormancy and stays dormant -- ...
Cached Medicine News:Health News:Reknowned Orthopaedic Surgeon to be Installed as President of Sports Medicine Society 2Health News:Reknowned Orthopaedic Surgeon to be Installed as President of Sports Medicine Society 3Health News:Reknowned Orthopaedic Surgeon to be Installed as President of Sports Medicine Society 4Health News:Ambulatory Services of America, Inc. Announces Joint Venture to Operate Radiation Oncology Facility in Dallas, Texas 2Health News:Indiana State Medical Association and AARP Urge Reconsideration of Bill to Protect Seniors' Access to Doctors and Improve Medicare 2Health News:Indiana State Medical Association and AARP Urge Reconsideration of Bill to Protect Seniors' Access to Doctors and Improve Medicare 3Health News:Next generation data analysis for next generation sequencing data 2Health News:New Hope Against the Cold Sore Virus 2Health News:New Hope Against the Cold Sore Virus 3
... establish the patient reportable range and establish ... Linearity is available in five-vial sets with ... 3700 and 4000; Bayer ADVIA 120; Coulter ... 755; Sysmex R-3000, R-3500, R-1000, RAM-1, XE-2100 ...
... CVA for CELL-DYN are assayed linearity control ... and to verify patient reportable range of ... also measure the linear performance of the ... have customized ranges appropriate for each instrument ...
... red blood cell (nRBC) control for evaluating the ... 755 hematology analyzer in its enumeration of the ... LH 750/LH 755. nRBC-Chex for LH is a ... for LH has a 75-day closed-vial stability and ...
... Sickle-Chex is a positive and negative whole ... of Hemoglobin S in solubility tests and ... SICKLEDEX and other manufacturers' solubility kits. ... squeeze dropper vial. The vial dispenses an ...
Medicine Products: